Paolo A. Ascierto: A Major Milestone for Melanoma Patients
Paolo A. Ascierto, Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Cancer Institute IRCCS Pascale Foundation, shared a post on LinkedIn:
“A major milestone for melanoma patients!
Thanks to a request submitted by AIOM (Italian Association of Medical Oncology), the drug combination investigated in the NADINA trial, has been included among the treatments reimbursed by the Italian National Health Service (SSN) under Law 648/96, for use as neoadjuvant therapy in patients with melanoma.
This approach involves priming the immune system before surgery with two cycles of immunotherapy using ipilimumab and nivolumab.
After surgery, the pathological response is assessed:
- If residual tumor cells are ≤10% (major pathological response – MPR), no further immunotherapy is administered.
- If residual disease is >10% (partial or no pathological response), adjuvant therapy with single-agent nivolumab continues for 11 additional cycles.
The NADINA trial results are clear:
- Higher pathological response rates
- Improved event-free survival (EFS)
- Potential to reduce post-operative treatments in responders
A true paradigm shift in melanoma management, enabling more targeted, effective, and personalized care.
Our thanks to AIOM for making this significant advancement possible!”
More posts featuring Paolo A. Ascierto.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023